Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20-year-old drug, with two tiers of pricing. By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. The Biden Administration’s Inflation Reduction Act will allow the government’s Medicare program for people aged 65 and older to negotiate prices of its most costly medicines, but drugs like Humira with direct competition are excluded.